NeoGenomics, Inc. (NASDAQ:NEO) Director Sells $291,738.33 in Stock
NeoGenomics, Inc. (NASDAQ:NEO) Director Bruce K. Crowther sold 8,333 shares of the firm’s stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $35.01, for a total value of $291,738.33. Following the completion of the sale, the director now directly owns 46,483 shares in the company, valued at $1,627,369.83. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NEO opened at $35.82 on Friday. NeoGenomics, Inc. has a 1 year low of $18.52 and a 1 year high of $41.03. The company has a debt-to-equity ratio of 0.25, a current ratio of 6.79 and a quick ratio of 6.44. The company has a market capitalization of $3.96 billion, a price-to-earnings ratio of -716.40 and a beta of 0.80. The business has a 50-day moving average of $37.69 and a 200-day moving average of $31.52.
NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. The company had revenue of $86.90 million during the quarter, compared to the consensus estimate of $86.55 million. NeoGenomics had a positive return on equity of 0.73% and a negative net margin of 1.33%. The firm’s revenue was down 14.6% compared to the same quarter last year. During the same period last year, the company earned $0.07 earnings per share. As a group, sell-side analysts anticipate that NeoGenomics, Inc. will post -0.01 EPS for the current year.
Hedge funds have recently modified their holdings of the business. Cullen Frost Bankers Inc. bought a new stake in NeoGenomics in the second quarter worth approximately $31,000. Carroll Financial Associates Inc. bought a new stake in NeoGenomics in the second quarter worth approximately $31,000. C M Bidwell & Associates Ltd. bought a new stake in NeoGenomics in the first quarter worth approximately $30,000. Prime Capital Investment Advisors LLC grew its stake in NeoGenomics by 108.3% in the second quarter. Prime Capital Investment Advisors LLC now owns 2,083 shares of the medical research company’s stock valued at $65,000 after acquiring an additional 1,083 shares during the period. Finally, Jacobi Capital Management LLC grew its stake in NeoGenomics by 70.1% in the second quarter. Jacobi Capital Management LLC now owns 3,401 shares of the medical research company’s stock valued at $62,000 after acquiring an additional 1,401 shares during the period. Institutional investors and hedge funds own 91.67% of the company’s stock.
Several analysts recently weighed in on NEO shares. Zacks Investment Research lowered NeoGenomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 7th. Needham & Company LLC increased their target price on NeoGenomics from $33.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Morgan Stanley started coverage on NeoGenomics in a research report on Wednesday, September 9th. They issued an “overweight” rating and a $46.00 target price for the company. SVB Leerink increased their target price on NeoGenomics from $35.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, BidaskClub downgraded NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 5th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $37.50.
About NeoGenomics
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
See Also: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source